RecruitingPhase 3NCT06228079

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eye & ENT Hospital of Fudan University
Principal Investigator: Hongmeng Yu
Eye& ENT Hospital, Fudan University
Intervention: Immunotherapy,Toripalimab Injection(drug)
Enrollment: 176 target
Eligibility: 18-75 years · All sexes
Timeline: 2024 – 2028

Study locations (7)

Eye& ENT Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Fujian Medical University Union Hospital, Fuzhou, China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
Changhai Hospital, Shanghai, China
Shanghai Sixth People's Hospital, Shanghai, China
Shanghai Zhongshan Hospital, Shanghai, China
Shenzhen Second People's Hospital, Shenzhen, China

Collaborators

Shanghai Zhongshan Hospital · Shanghai 6th People's Hospital · Changhai Hospital · Fujian Medical University Union Hospital · People's Hospital of Guangxi Zhuang Autonomous Region · Shenzhen Second People's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06228079 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials